Articles by The Wall Street Analyzer

About The Wall Street Analyzer
The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum.
News Feed

Citius Pharmaceuticals Acquires Dr. Reddy’s Laboratories’ License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications

September 7, 2021 The Wall Street Analyzer Comments Off on Citius Pharmaceuticals Acquires Dr. Reddy’s Laboratories’ License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications

Citius expands late-stage pipeline with the acquisition of Dr. Reddy’s exclusive license rights to E7777, an improved formulation of previously FDA-approved ONTAK®; the exclusive license is with Eisai Co. Ltd.Patient enrollment has been completed in […]

No Picture
News Feed

Pennexx Builds a Powerhouse of Advisory Board Members Bringing over 100 Years of Executive Marketing and Business Experience to the Company and its Shareholders to Continue the Implementation of YourSocialOffers.com (YSO).

August 18, 2021 The Wall Street Analyzer Comments Off on Pennexx Builds a Powerhouse of Advisory Board Members Bringing over 100 Years of Executive Marketing and Business Experience to the Company and its Shareholders to Continue the Implementation of YourSocialOffers.com (YSO).

PHILADELPHIA, PA / ACCESSWIRE / August 17, 2021 / Pennexx’s (OTCMKTS:PNNX) powerhouse advisory board discussed continued implementation and growth plans for https://YourSocialOffers.com (YSO). Pennexx hosted this valuable workshop with our newly formed Advisory Board Members: Mr. Tom Coba […]